ESC Premium Access

Impact of polypharmacy on prognosis in patients with acute decompensated heart failure: from the CURE-HF registry

Presentation

About the speaker

Doctor Masafumi Kanai

Shinshu University Hospital, Matsumoto (Japan)
0 follower

218 more presentations in this session

Intermittent therapy with levosimendan in patients with advanced heart failure

Speaker: Professor M. Weis (Munich, DE)

Thumbnail

Differences in long-term all-cause and cardiovascular mortality according to heart failure aetiology in ambulatory patients

Speaker: Doctor G. Spitaleri (Badalona, ES)

Thumbnail

Comparing the central arterial stiffness indices in the decompensated and compensated states of heart failure: a cohort study

Speaker: Assistant Professor G. Youssef (Cairo, EG)

Thumbnail

Opportunities for clinician education in the pharmacotherapy of stable heart failure

Speaker: Doctor P. Murray (Dublin, IE)

Thumbnail

Systolic blood pressure visit-to-visit variability and clinical outcomes of heart failure with preserved ejection fraction

Speaker: Doctor Q. Zhang (Tianjin, CN)

Thumbnail

Access the full session

Chronic heart failure e-posters

Speakers: Doctor M. Kanai, Professor M. Weis, Doctor G. Spitaleri, Assistant Professor G. Youssef, Doctor P. Murray...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial

27 August 2021

ESC Premium Access

Hemoglobin, anemia, and clinical outcomes in vericiguat global study in subjects with heart failure with reduced ejection fraction (VICTORIA)

27 August 2021

ESC Premium Access

Vericiguat and health status outcomes in heart failure with reduced ejection fraction: Insights from the VICTORIA trial

27 August 2021

This platform is supported by

logo Novo Nordisk